

SOP number	53.003	Version	5.0
Title	Temporary Halt or Early Termination of Clinical Trials of Investigational Medicinal Products		

Prepared by	Caroline Watson
Approved by	Chloe Cowan
Released by	Jesse Dawson

SOP category	NHS GG&C Sponsor Governance			
Staff category				
Staff Category	R	A	C	I
Research Governance Manager		X		
Lead Pharmacist Clinical Trials R&I	X			
Project Managers	X			
All R&I Staff	X			
Chief Investigators (NHSGGC Sponsored and Co-Sponsored trials)	X			
Principal Investigators	X			
Glasgow University Research Governance Team	X			

1. Scope

This procedure applies to all trials Sponsored/Co-Sponsored and hosted by NHS Greater Glasgow and Clyde Board (NHSGGC) and staff involved in this activity.

2. Purpose

The purpose of this SOP is to describe how NHS Greater Glasgow & Clyde (NHSGGC) halts or terminates early non commercial (academic) clinical trials Sponsored or Co-Sponsored by NHSGGC in compliance with Regulation 27 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (Statutory Instrument 2004/1031) as amended.

3. Procedures

3.1. Temporary Halt of a Trial or a Location Involved In a Trial

The R&I Director, a Sponsor's representative and/or the Investigator is responsible for the decision to temporarily halt or terminate early a clinical trial, e.g. following a recommendation from an independent data monitoring committee, a series of non-compliance or safety issue.

If a trial or a location is temporarily halted or terminated early the Glasgow Health Science Partnership Regulatory Affairs Group, (GHSP RAG) will be informed.

An appropriate representative of the Sponsor, in conjunction with the Chief Investigator, must notify the Medicines and Healthcare products Regulatory Agency (MHRA) and relevant ethics committee within 15 calendar days of the decision to halt the trial or halt a trial location.

The notification must be made as a substantial modification to the MHRA using the Notification of Modification form, clearly explaining what has been halted (i.e. stopping recruitment and/or interrupting treatment of participants already included) and the reason(s) for the halt.

NHSGGC and the Investigator may halt a trial as an urgent safety measure in order to protect the participants of a clinical trial against any immediate hazard to their health and safety. Urgent safety measures can be implemented immediately and prior to authorisation from the MHRA and relevant ethics committee. In that case, SOP 53.001 handling urgent safety measures for clinical trials of investigational medicinal products must be followed. Protocol waivers are not permitted. However, in case of deviations undertaken to eliminate immediate hazard to trial participants, the investigator will inform the sponsor promptly. The MHRA must be notified immediately, (or no later than 3 calendar days from the date the measures were taken) the MHRA and relevant ethics committee of the measures taken and the circumstances.

If the MHRA removes its approval and/ or REC may remove its favourable opinion for a trial the Sponsor and Investigator will submit the substantial modification and inform the trial locations.

If the trial is prematurely terminated or suspended for any reason, the investigator/location institution, under the guidance of the Sponsor, will promptly inform the trial participants and will ensure appropriate therapy and follow-up for the participants. The Project Manager is responsible for informing the trial locations to notify the participants that the trial is prematurely terminated/suspended and to request that the location undertake the appropriate management of the participants. If a trial is first suspended and then terminated the reporting of a substantial modification is required each time .

3.2. To Restart a Trial or a Trial Location

To restart a trial or a trial location that has been temporarily halted, an appropriate representative of the Sponsor, in conjunction with the Chief Investigator, shall make the request as a substantial modification to the MHRA and relevant Ethics Committee using the Notification of Modification form.

The substantial modification notification must include evidence that it is safe to restart the trial.

The R&I Director or a Sponsors' representative is responsible for the decision to restart a trial or a trial location. The decision to restart a trial may only be taken following approval of the substantial modification by the MHRA and relevant Ethics Committee. The Chief Investigator will be notified of the restart date and any relevant conditions.

GHSP RAG will be informed when the trial is re-started and may make recommendations.

3.3. Trial Does Not Recommence (Termination)

This following procedure is only relevant when a trial and not individual trial locations does not recommence.

If the trial does not recommence following a temporary halt, an appropriate representative of the Sponsor must submit an End of Trial Declaration form to the MHRA and relevant Ethics Committee within 15 calendar days of the decision. This will be done in conjunction with the Chief Investigator.

A cover letter will also be submitted which includes:

- Name and address of Sponsor's legal representative
- Title of trial
- Trial protocol code number
- Date of end of trial in member state concerned
- Date of end of complete trial in all participating centres

When the trial is terminated early, the end of clinical trial report will also provide the following information:

- Justification of the premature ending of the trial
- Number of participants still receiving treatment at the time of study termination
- Proposed management of participants receiving treatment at time of study termination
- Consequences for the evaluation of results.
- The participants will be notified.

4. Referenced documents

- SOP 53.001 - Handling urgent safety measures for clinical trials of investigational medicinal products

5. Related documents

- Glasgow Health Science Partnership Regulatory Affairs Group Terms of Reference
- SOP 51.008 - Handling non compliance with Good Clinical Practice (GCP) and/or the trial protocol in clinical research
- SOP 53.002 - The Handling of Poor Quality and Fraud in Clinical Research

6. Document history

Version	Date	Description	Retrospective Implementation
1.0	18/06/09	Release of Version 1.0	No
1.1	04/11/13	Change to staff category, sponsor representatives or NHS staff who can stop and start trials. Inclusion of procedures when a trial site is temporarily halted.	No
2.0	15/07/2016	Updated to template v1.4.	No
3.0	04/01/2019	Temporary change to Author. Revised Governance structures (RAGs) updated. GU Governance staff added in staff category. "Approved" & "Released by" updated. No changes made to process.	No
4.0	25/01/2024	Change back to original author, RACI matrix added, clarification on halt due to urgent safety measure. Update link to end of trial declaration form link.	No
5.0	23/06/2026	ICH GCP R3 incorporated to include notifying participants	No

This SOP is a controlled document. The current version can be viewed on the R&I website, GCTU website and R&I's Q-Pulse account.

Any copy reproduced from the website may not, at time of reading, be the current version.